Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Cancer immunotherapies are effective but many patients develop resistance.
• Resistance often involves mechanisms that impair neo-antigen presentation on MHC I molecules.
• Natural killer (NK) cells represent a promising therapeutic avenue against immune-evasive tumors.

Purpose of the Study:

• To identify genes that limit NK cell anti-tumor activity using genome-wide CRISPR/Cas9 screens.
• To understand the mechanisms by which tumor cells evade immune surveillance.
• To explore NK cell-based strategies to overcome resistance to current cancer immunotherapies.

Main Methods:

• Genome-wide CRISPR/Cas9 screening in cancer cells.
• Analysis of antigen presentation pathways and interferon-gamma (IFN-γ) signaling.
• Assessment of tumor cell sensitivity to NK cell-mediated killing.
• Investigation of MHC I expression regulation in response to IFN-γ.

Main Results:

• Genes involved in antigen presentation and IFN-γ signaling protect tumor cells from NK cell killing.
• Jak1-deficient melanoma cells showed increased sensitivity to NK cells due to impaired IFN-γ signaling and MHC I expression.
• Tumor cells resistant to T cell-mediated killing, often lacking MHC I, were highly susceptible to NK cell cytotoxicity.
• Identified genes that tumor cells exploit for checkpoint blockade resistance also increase vulnerability to NK cells.

Conclusions:

• Tumor cells utilize specific genetic pathways to resist T cell-based immunotherapies.
• These resistance mechanisms simultaneously sensitize tumors to NK cell-mediated killing.
• NK cell-based immunotherapies can be a potent strategy to overcome immune escape in cancer.